O'Day on remdesivir: ‘We will not get in a patent dispute’

Gilead CEO Daniel O’Day said a patent application from two Chinese institutions for the use of the company’s unapproved antiviral remdesivir to treat the coronavirus “has no impact on what we’re going to do for global health.”

“It’s tremendously clear that our responsibility is to patients, and our number one responsibility is to pursue the right clinical programs to determine whether or not this medicine has an impact with patients,” according to remarks O’Day made at a company meeting that were made available on YouTube. “We will not get into a patent dispute; we will find a way to help patients.”...